louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05057091: Immediate Effects of Two Spinal Manipulative Techniques
Official title: Immediate Effects of Two Spinal Manipulative Techniques on Clinical Outcomes and Muscle Mechanical Properties in Chronic Low Back Pain: An Assessor Blinded, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Low-back Pain
Keywords: Acute Manipulation
Chronic manipulation
Low back pain
muscles mechanical treshold
physiotherapy
Lead sponsor: Alanya Alaaddin Keykubat University
Sponsor class: OTHER
First posted: 2021-09-27
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This research is planned as a double blind randomized controlled trials
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the instant effects of direct vertabral manipulation and indirect vertebral manipulation techniques on muscles mechanical properties, pressure-pain threshold and joint range of motion in individuals with chronic low back pain. Another purpose of this study was to compare the effects of both treatment methods on the parameters studied.

Detailed description: Resolving chronic low back pain is a costly obstacle. There is a wide spectrum of treatment for chronic low back pain, such as exercise training, pain training and spinal manipulation.It is the recommended spinal manipulation in the short and long term in chronic low back pain. Clinical Spinal manipulation is one of the most preferred methods of reducing pain and disability.

Eligibility criteria: Inclusion Criteria:

* 18-65 ages
* Individuals with non-specific chronic low back pain who have continued pain for at least 3 months
* According to VAS, individuals with pain of at least 3 severity

Exclusion Criteria:

* Pregnancy situation or suspicion
* Spinal Stenosis
* Vertebral fracture
* Cancer
* Osteoporosis
* Individuals with BMI over 30 kg/m2
* Those with neurological disease that leads to November loss of muscle strength or spasticity-rigidity

Primary outcomes:
measure: Mechanical properties measurements
timeFrame: through study completion, an average of 1 hour
Secondary outcomes:
measure: Oswestry low back pain scale
timeFrame: Through study completion, an average of 1 hour
measure: Roland morris disability scale
timeFrame: Through study completion, an average of 1 hour
measure: Visual analog scale
timeFrame: Through study completion, an average of 1 hour
measure: Fear Avoidance Beliefs Questionnare
timeFrame: Through study completion, an average of 1 hour
Other outcomes:
measure: Modify shober test
timeFrame: The measurements were performed before and immediately after the applications.
measure: Sit and reach tets
timeFrame: The measurements were performed before and immediately after the applications.
Locations:
city: Antalya
country: Turkey
facility: Alanyaaku
state: Alanya
Study officials:
affiliation: Alanya Alaaddin Keykubat University
name: Emine KURT, Assc. Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04869891: How Much The Self-Reported Physical Activity Change in Patients With Physical Disabilities Hospitalized for Rehabilitation in A Physical Medicine and Rehabilitation Clinic
Official title: How Much The Self-Reported Physical Activity Change in Patients With Physical Disabilities Hospitalized for Rehabilitation in A Physical Medicine and Rehabilitation Clinic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Disability Physical
Impairment
Physical Activity
Rehabilitation
Televisit
Lead sponsor: Diskapi Yildirim Beyazit Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2021-05-03
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with physical disabilities, due to neurologic or musculoskeletal diseases and hospitalized in PMR clinic for rehabilitationbetween September 2020 andMarch 2021were

Brief summary: Disability was defined by WHOas a restriction or lack of ability to perform daily activity, but this definition was later changedto problems in functioning in the WHO classification of Functioning, Disability and Health (ICF). Osteoarthritis, back pain, neck pain, rheumatologic diseases, neurologic disorders (stroke, spinal cord injury, multiple sclerosis, Parkinson diseases) can cause physical disabilities.Recent studies have shown that; high levels ofdisability is related with low levels of physical activity.Individuals with disability are commonly hospitalized ininpatients clinicsfor rehabilitation, which aims to achieveoptimal functional level ofpatients within their own limitations.A rehabilitation program can be an excellent opportunity to integrate post-rehabilitation physical activity into their lifestyle.This study aimed to examine the short term effect of inpatient rehabilitation program on self -reported physical activity both participants with physical disabilities due to musculoskeletal, and neurological disorders


Eligibility criteria: Inclusion Criteria:

* Patients with physical disabilities, due to neurologic or musculoskeletal diseases and hospitalized in PMR clinic for rehabilitation between Patients over 18 years of age with cognitive functions able to fill the forms and patients with medical stabilization for neurological diseases.

Exclusion Criteria:

* Patients under 18 years of age,
* Patients with additional hearing, visual and mental disabilities
* Patients with metabolic instability for neurological diseases, history of malignancyand pulmonary and cardiac failure,
* Patients with recurrent hospitalization in the PMRclinic

Primary outcomes:
measure: PASIPD
timeFrame: 15 MİNUTES
Secondary outcomes:
Other outcomes:
Locations:
city: Çankaya
country: Turkey
facility: DiskapiYBERH
state: Ankara
Study officials:
References:
Clinical trial NCT04049591: Higher vs. Lower Dose Heparin for PCI
Official title: A Randomized Trial of Higher vs. Lower Dose Heparin for PCI
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiovascular Diseases
Percutaneous Coronary Intervention
Lead sponsor: Population Health Research Institute
Sponsor class: OTHER
First posted: 2019-08-08
Enrollment: 16000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Cluster crossover
Primary purpose: PREVENTION

Brief summary: HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).

Detailed description: The primary objective of HD PCI is to compare the effect of a policy of higher dose heparin (100 U/kg) use to a policy of lower dose heparin (70 U/kg) use on death, myocardial infarction (MI) or target vessel revascularization (TVR) in patients undergoing elective percutaneous coronary intervention (PCI).

Eligibility criteria: Inclusion Criteria:

- Patients undergoing elective PCI

Exclusion Criteria:

* Age \<18 years
* Planned chronic total occlusion PCI
* Non-resident precluding follow up through local registries

Hospital (Cluster) Eligibility Criteria

Hospitals will be eligible to participate if they meet the following criteria:

* Submit PCI procedure data to a compatible registry that is able to provide data for the trial
* Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period

Primary outcomes:
measure: Number of Participants with any of the following: death, myocardial infarction or target vessel revascularization
timeFrame: up to 30 days after PCI
Secondary outcomes:
measure: Number of Participants with major bleeding
timeFrame: up to 30 days after PCI
measure: Number of Participants with any of the following: death, myocardial infarction, target vessel revascularization or major bleeding
timeFrame: up to 30 days after PCI
Other outcomes:
measure: Number of Participants with either of the following: death or myocardial infarction
timeFrame: up to 30 days after PCI
measure: Number of Participants with definite stent thrombosis
timeFrame: up to 30 days after PCI
Locations:
city: Hamilton
country: Canada
facility: Hamilton Health Sciences, General Hospital
state: Ontario
Study officials:
affiliation: Population Health Research Institute
name: Sanjit Jolly, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05017194: Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
Official title: Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm: Randomized Two Stages Phase II Seamless Adaptive Controlled Single-blind Trials
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Trichuris Trichiura; Infection
Hookworm Infections
Keywords: Emodepside
Trichuris trichiura
Hookworm
Soil-transmitted helminths
Efficacy
Safety
Dose selection
Lead sponsor: Swiss Tropical & Public Health Institute
Sponsor class: OTHER
Collaborators: name: Public Health Laboratory Ivo de Carneri
First posted: 2021-08-23
Enrollment: 442
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The rationale of the study is to provide evidence on the efficacy and safety of Emodepside in adults infected with Trichuris trichiura and hookworm.


Eligibility criteria: Inclusion Criteria:

* Male or female adults aged between 18 and 45 years
* Written and signed informed consent
* Examined by a study physician before treatment
* Provided two stool samples at baseline
* Trichuris trichiura and hookworm EPG ≥ 48 and at least two Kato-Katz thick smears slides with more than one Trichuris trichiura and hookworm eggs

Exclusion Criteria:

* Pregnant or lactating and/or planning to become pregnant within three months after drug treatment
* Type 1 and/or 2 diabetes
* Psychiatric disorders
* History of ophthalmological conditions
* Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment
* Suffers from severe anaemia (Hb \< 80 g/l)
* Received anthelminthic treatment within past four weeks
* Attending other clinical trials during the study
* Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin
* Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir

Primary outcomes:
measure: Cure rate (CR) of emodepside against Trichuris trichiura
timeFrame: In the week between 14 and 21 days post-treatment
measure: Cure rate (CR) of emodepside against hookworm
timeFrame: In the week between 14 and 21 days post-treatment
Secondary outcomes:
measure: Geometric Mean Egg Reduction Rate (ERR) of the emodepside against Trichuris trichiura and hookworm.
timeFrame: In the week between 14 and 21 days post-treatment
measure: CR against Ascaris lumbricoides
timeFrame: In the week between 14 and 21 days post-treatment
measure: ERR against Ascaris lumbricoides
timeFrame: In the week between 14 and 21 days post-treatment
Other outcomes:
Locations:
city: Chake Chake
country: Tanzania
facility: Public Health Laboratory - Ivo de Carneri
Study officials:
References:
Clinical trial NCT05344794: Relationship Between Serum N/OFQ and Brain-heart Syndrome
Official title: Relationship Between Serum N/OFQ and Cerebral Cardiac Syndrome After Stroke
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cerebral-Cardiac Syndrome
Lead sponsor: Second Hospital of Shanxi Medical University
Sponsor class: OTHER
First posted: 2022-04-25
Enrollment: 120
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in the Second Hospital of Shanxi Medical University from May 2022 to October 2023

Brief summary: Choosing the neurology patients in the Second Hospital of Shanxi Medical University, diagnosed with patients with cerebral syndrome into the experimental group; patients who did not have cerebral syndrome included in the control group, and all selected people had no intimate relationship with each other.Specimen collecting control group and the study group serum inflammatory factor IL-6, solvent peptide and catecholamine content. The difference between the two groups of data was observed.According to the literature, it is guess: The solitary peptide content of the experimental group will be higher than the control group, and is positively correlated with IL-6, catecholamine content.The difference was statistically significant.


Eligibility criteria: Inclusion Criteria:

* Diagnostic criteria in compliance with cerebral syndrome
* Acute ischemic stroke patients in line with the "Chinese Acute Ischemic Stroke Treatment Guide 2018" related diagnostic criteria
* There is no intimate relationship between all selected people and knows this study, and signs informed consent

Exclusion Criteria:

* Heart-type cerebral infarction, hemorrhagic stroke, brain tumor and past intracranial hemorrhage
* Complicated with severe cardiovascular complications (such as coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic heart failure, atrial fibrillation, etc.)
* Complicated with severe liver and kidney dysfunction (such as coagulous dysfunction, cirrhosis, nephrotic syndrome , Renal failure, etc.)
* Complicated with severe diabetes complications (such as diabetic nephropathy, diabetic foot, diabetic acidosis, high blood sugar hypertonic state, diabetes coronary heart disease, etc.)
* Complicated with Psychological disease
* Complicated with chronic obstructive pulmonary disease(COPD)
* BMI\> 40

Primary outcomes:
measure: N/OFQ
timeFrame: 24 hours
measure: IL-6
timeFrame: 24 hours
measure: NE
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Taiyuan
country: China
facility: Second of Shanxi Medical University
state: Shanxi
Study officials:
References:
Clinical trial NCT01888094: SUBclavian Central Venous Catheters Guidance and Examination by UltraSound
Official title: SUBclavian Central Venous Catheters Guidance and Examination by UltraSound : a Randomized Controlled Study Versus Landmark Method
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Requiring Subclavian Vein Cannulation
Adult Patients
Patient Covered by French Health Care System
Keywords: Central venous catheter
Complications
Ultrasound
Subclavian vein cannulation
Critical care
Echocardiography
Chest radiographyiography
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2013-06-27
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound

Detailed description: One groupe : Ultrasound guided for cannulation and examination of absence ofcomplications One groupe : landmark method and examination with chest radiography

Eligibility criteria: Inclusion Criteria:

* adults patients
* requiring subclavian vein cannulation
* patient covered by french health care system

Exclusion Criteria:

* patient refusal
* requiring vein cannulation femoral or jugular
* we see nothing with echocardiography
* children and not adult patients

Primary outcomes:
measure: procedure time between the beginning of procedure ( TO) and when the catheter is controlled ( T4) between strategy catheter cannulation 'standard' and a strategy called "ultrasound all
timeFrame: at day 1
Secondary outcomes:
measure: procedure time Tn-Tn (n 0-5) between the two strategies.
timeFrame: at day 1
measure: incidence of occurrence of complications: pneumothorax, hemothorax, bad positioning (outside of the superior vena cava or the right atrium) between the two strategies
timeFrame: at day 1
measure: failure of technology between the two strategies.
timeFrame: at day 1
measure: occurrence of central venous catheter infection.
timeFrame: at day 1
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Sébastien PERBET
role: PRINCIPAL_INVESTIGATOR
References:
citation: Perbet S, Pereira B, Grimaldi F, Duale C, Bazin JE, Constantin JM. Guidance and examination by ultrasound versus landmark and radiographic method for placement of subclavian central venous catheters: study protocol for a randomized controlled trial. Trials. 2014 May 20;15:175. doi: 10.1186/1745-6215-15-175.
Clinical trial NCT03097094: Precision Allergy: Separate Allergies to Male and Female Dogs
Official title: Precision Allergy: Separate Allergies to Male and Female Dogs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Allergy; Dander
Keywords: Dog allergy
Can f 5
Male dog
Female dog
Allergen components
Lead sponsor: Copenhagen Studies on Asthma in Childhood
Sponsor class: OTHER
First posted: 2017-03-31
Enrollment: 22
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: A new male-specific dog-allergen-component has been found (Can f 5) which indicates possible differences in allergic reactions to male and female dogs. This has not yet been tested in real life.

The aim is to test if sensitization only to the male-dog specific allergen-component, Can f 5, results in a positive skin prick test (SPT) to male dog extract and not female dog extract. In addition, the investigators want to investigate if allergic symptoms only occur when exposed to the male dog extract by conjunctival provocation.


Eligibility criteria: Inclusion Criteria:

* Participants in the COPSAC 2000 cohort
* Positive component test (\>0.3 ISU) to Can f 1, Can f 2, Can f 3 or Can f 5

Exclusion Criteria:

* Uncontrolled asthma
* Eye-surgery within the past 6 months
* Antihistamine allergy
* and others

Primary outcomes:
measure: Male vs. female dog SPT in Can f 5 mono sensitized patients
timeFrame: 6 months
Secondary outcomes:
measure: Male vs. female dog conjunctival provocation in Can f 5 mono sensitized patients
timeFrame: 6 months
measure: Male vs. female dog SPT in dog poly sensitized patients
timeFrame: 6 months
measure: Male vs. female dog conjunctival provocation in dog poly sensitized patients
timeFrame: 6 months
measure: Can f 5 vs. SPT size
timeFrame: 6 months
measure: Can f 5 vs. conjunctival provocation
timeFrame: 6 months
measure: SPT vs. conjunctival provocation
timeFrame: 6 months
Other outcomes:
Locations:
city: Gentofte
country: Denmark
facility: Copsac, Dbac
state: Copenhagen
Study officials:
affiliation: Copenhagen Studies on Asthma in Childhood
name: Klaus Bønnelykke, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02085694: Lactobacillus Brevis CD2 Preventing Oral Mucositis
Official title: A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Mucositis
Lead sponsor: Catholic University of the Sacred Heart
Sponsor class: OTHER
First posted: 2014-03-13
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: A pilot study on efficacy of Lactobacillus CD2 lozenges in preventing oral mucositis (OM) by high-dose chemotherapy with autologous hematopoietic stem cell transplantation. To test whether the probiotic Lactobacillus brevis CD2 lozenges can reduce the incidence and severity of high-dose chemotherapy conditioning regimen induced OM in patients undergoing HSCT.

Clinical activity will be defined as reduction in the incidence of chemotherapy induced OM in the patients undergoing HSCT.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 65 years
* Karnofsky Performance Score ≥ 70%.
* Confirmed histological diagnosis of multiple myeloma for which HSCT is as approved modality of therapy
* Patients eligible to receive high-dose chemotherapy as part of conditioning regimen
* Concomitant co morbid condition if present, controlled by ongoing treatments (e.g. hypertension, diabetes and so on)
* Serum creatinine \< 1.8mg/dl
* Total bilirubin \< 2mg/dl
* Liver enzymes within three times of normal limit
* Expected survival \> 6 months.

Exclusion Criteria:

* Pregnant women and lactating mothers
* Patients with history of HIV infection
* Patients who have taken any other investigational product in last 4 weeks
* Patients having untreated symptomatic dental infection
* Patients with WHO Grade 3 or 4 oral Mucositis
* Other serious concurrent illness
* Inconclusive hematological diagnosis
* Patients with signs and symptoms of systemic infections
* Patient's/guardian's refusal to sign informed consent

Primary outcomes:
measure: COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS v4.03 (CTCAE) for evaluation of change in oral mucositis
timeFrame: days -14;-7; 0;+7;+14;+21
Secondary outcomes:
measure: COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS v4.03 (CTCAE) to determine the incidence of Grade I and II OM
timeFrame: days -14;-7; 0; +7;+14; +21
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Policlinico Universitario "A. GEMELLI"
Study officials:
References: